BR9912279A - Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas - Google Patents

Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas

Info

Publication number
BR9912279A
BR9912279A BR9912279-0A BR9912279A BR9912279A BR 9912279 A BR9912279 A BR 9912279A BR 9912279 A BR9912279 A BR 9912279A BR 9912279 A BR9912279 A BR 9912279A
Authority
BR
Brazil
Prior art keywords
uteroglobin
recombinant human
inflammatory
treatment
receptor
Prior art date
Application number
BR9912279-0A
Other languages
English (en)
Inventor
Aprile Pilon
Anil B Mukherjee
Zhongjian Zhang
Original Assignee
Claragen Inc
Nat Inst Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claragen Inc, Nat Inst Health filed Critical Claragen Inc
Publication of BR9912279A publication Critical patent/BR9912279A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE UTEROGLOBINA HUMANA RECOMBINANTE NO TRATAMENTO DE CONDIçõES INFLAMATóRIAS E FIBRóTICAS". A presente invenção refere-se e reivindica composições e a métodos para prevenir ou tratar crescimento de células cancerosas primárias e metástase de tumor, bem como estimulação de hematopoiese. A presente invenção também refere-se a métodos de tratamento de câncer e condições relacionadas a receptor de uteroglobina almejando-se um receptor de uteroglobina com uteroglobina humana recombinante (rhUG). São também descritos e reivindicados métodos de purificação de um receptor de uteroglobina e método para usar tais receptores na identificação de análogos estruturais de uteroglobina e ligandos de receptor de UG.
BR9912279-0A 1998-07-21 1999-07-19 Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas BR9912279A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/120,264 US20020160948A1 (en) 1998-07-21 1998-07-21 Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
PCT/US1999/016312 WO2000004863A2 (en) 1998-07-21 1999-07-19 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions

Publications (1)

Publication Number Publication Date
BR9912279A true BR9912279A (pt) 2002-01-02

Family

ID=22389207

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912279-0A BR9912279A (pt) 1998-07-21 1999-07-19 Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas

Country Status (10)

Country Link
US (1) US20020160948A1 (pt)
EP (1) EP1100524A4 (pt)
JP (1) JP2002521316A (pt)
KR (1) KR20010085294A (pt)
CN (1) CN1323216A (pt)
AU (1) AU5112499A (pt)
BR (1) BR9912279A (pt)
CA (1) CA2338299A1 (pt)
IL (1) IL140926A0 (pt)
WO (1) WO2000004863A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122344B2 (en) * 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20060025348A1 (en) * 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
AU5836700A (en) * 1999-06-01 2000-12-18 Patrick T. Prendergast Peptides for therapeutic use
US20040153073A1 (en) 2000-02-01 2004-08-05 Hand Innovations, Inc. Orthopedic fixation system including plate element with threaded holes having divergent axes
CN1315370A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人子宫珠蛋白11和编码这种多肽的多核苷酸
AU2000243657A1 (en) * 2000-04-21 2001-11-07 George Washington University Method of binding integrin for treatment of cancer
CN1323824A (zh) * 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人子宫珠蛋白9和编码这种多肽的多核苷酸
NZ588895A (en) 2008-05-13 2012-07-27 Clarassance Inc Recombinant human CC10 (rhCC10 aka uteroglobin) and compositions thereof for use in the treatment of nasal rhinitis
US8293100B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
CA2813740C (en) 2009-10-15 2016-08-02 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
EP2531208A4 (en) * 2010-02-03 2013-07-03 Univ Rochester TREATMENT OF FIBROSIS RELATED DISORDERS USING FIBRONECTIN BINDING PROTEINS AND POLYPEPTIDES
WO2019176866A1 (ja) * 2018-03-12 2019-09-19 国立研究開発法人医薬基盤・健康・栄養研究所 ウテログロビンを構造基盤とする二重特異性ポリペプチド

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696092A (en) * 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
JP4400934B2 (ja) * 1996-08-19 2010-01-20 アボット・ラボラトリーズ 胸部の疾患の検出に有用な試薬及び方法

Also Published As

Publication number Publication date
CA2338299A1 (en) 2000-02-03
WO2000004863A3 (en) 2000-11-23
WO2000004863A2 (en) 2000-02-03
EP1100524A2 (en) 2001-05-23
IL140926A0 (en) 2002-02-10
KR20010085294A (ko) 2001-09-07
EP1100524A4 (en) 2003-08-27
US20020160948A1 (en) 2002-10-31
AU5112499A (en) 2000-02-14
JP2002521316A (ja) 2002-07-16
CN1323216A (zh) 2001-11-21

Similar Documents

Publication Publication Date Title
BR9912279A (pt) Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
EP0792278A4 (en) TUMORNESCROSS FACTOR GAMMA
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
DK0839154T3 (da) Biologiske aktive peptider og præparater samt anvendelse deraf
PT917571E (pt) Gene relacionado com agouti
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
DK1000149T3 (da) 5'-EST'ere til udskilte proteiner identificeret fra hjernevæv
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
HK1033910A1 (en) Use of erythropoietin in the treatment of multiple myeloma
DE60143818D1 (de) Alpha-fetoprotein-peptide und ihre verwendung
ATE325089T1 (de) Krebsbehandlungsmittel für epithelzellen
ATE514718T1 (de) Peptabody für krebsbehandlung
NZ331063A (en) Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
DE60100855D1 (de) 1,8-naphthalimid imidazo[4,5,1-de]acridone mit antitumorwirkung
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
AR019844A1 (es) Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales
DE60239670D1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
EP0770137A4 (en) IMPROVEMENTS IN PROTEIN PRODUCTION IN HOST CELLS
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
DE60027928D1 (de) MENSCHLICHES, GEBäRMUTTERKREBS-SPEZIFISCHES SUPPRESSORPROTEIN, FüR DAS PROTEIN KODIERES POLYNUKLEOTID, MIT DEM POLYNUKLEOTID TRANSFORMIERTE ZELLE UND VERFAHREN ZUR UNTERDRüCKUNG DER PROLIFERATION VON KREBSZELLEN UNTER VERWENDUNG DES EXPRESSIONSVEKTORS
MX9805299A (es) Novedosos polinucleotidos panc1a y panc1b asociados con cancer pancreatico.
ATE314096T1 (de) Therapeutisch verwendbare triethylenglykol- cholesteryl-oligonukleotide

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.